-      Strand Life Science will provide their StrandOmics analysis platform in conjunction with Celemics bioinformatic pipeline, including assay-specific variant filters with a complete sample-to-report solution.

-      This partnership will help to provide guaranteed clinical-grade data compliance for customers

Under the agreement, Strand Life Science will integrate the Celemics bioinformatics pipeline into the StrandOmics tertiary analysis platform to enable Celemics with a complete sample-to-report solution.
Leveraging the StrandOmics platform, Celemics plans to serve an expanding global market with clinical-grade data compliance and guaranteed data residency for customers in Europe, Asia, and beyond.

Celemics Co-Founder and CEO Hyoki Kim said, “We are excited about this new partnership with Strand Life Sciences. Their expertise in the engineering of NGS systems and long track record with the instrument and diagnostic companies will be valuable in accelerating our path to market integration."

Also, Stand Life Sciences CEO Dr. Ramesh Hariharan said, "With our unique track record of running NGS labs as well as interpretation support for genetic tests, we are excited to partner with Celemics to help bring their cancer; inherited cancer, and rare disease panels to the market."

Founded in 2000 by academics from the Indian Institute of Science, Strand Life Sciences is a specialized genomics solutions company offering bioinformatics, knowledge-based curation development, software, assay design, and clinical research services globally, and also operates a diagnostics reference lab with a focus on genomics and oncology in India.

Celemics is a biotech company developing and supplying critical enabling solutions in genomics, antibody discovery, medicine, biopharma, microbiome, synthetic biology, and AgBio. 
Founded in 2010, Celemics has focused in the last several years on providing target enrichment panels to Europe and Asia for various applications, including oncology, inherited disease,
and genetic marker discovery.